Abiraterone Acetate

CHEMBL271227 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
391.5 g/mol
LogP
5.2
Phase
4

An oral medication that lowers testosterone and other androgens throughout the body by blocking an enzyme called CYP17 involved in their production. It is used to treat advanced prostate cancer that continues to grow despite standard hormone therapy, and must always be taken with a corticosteroid such as prednisone to prevent certain hormonal side effects. Patients need regular blood pressure and liver function monitoring during treatment.

الوزن الجزيئي

391,5000 g/mol

LogP

5,20

TPSA

39,20 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

آلية العمل

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(c4cccnc4)=CC[C@@H]32)C1

InChI

InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1

Molecular Formula

C26H33NO2

HBD / HBA

- / 3

الروابط القابلة للدوران

3

الذرات الثقيلة

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An oral medication that lowers testosterone and other androgens throughout the body by blocking an enzyme called CYP17 involved in their production. It is used to treat advanced prostate cancer that continues to grow despite standard hormone therapy, and must always be taken with a corticosteroid such as prednisone to prevent certain hormonal side effects. Patients need regular blood pressure and liver function monitoring during treatment.

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Yes, Abiraterone Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL271227. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9821849. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.